Cargando…

Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N(2) non-small cell lung cancer

BACKGROUND: Pathological stage III/N(2) non-small cell lung cancer (NSCLC) is heterogeneous, and the optimal prognostic marker for survival remains unclear in Chinese patients. The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Dong, Wei, Ping, An, Guangyu, Chen, Wenming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681661/ https://www.ncbi.nlm.nih.gov/pubmed/23759026 http://dx.doi.org/10.1186/1749-8090-8-149

Ejemplares similares

Associations of individual and joint expressions of ERCC6 and ERCC8 with clinicopathological parameters and prognosis of gastric cancer
por: Chen, Jing, et al.
Publicado: (2021)

ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
por: Wang, Xiyong, et al.
Publicado: (2017)

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010)

Prognostic Factors in Stage III Non-Small-Cell Lung Cancer Patients
por: Urvay, Semiha Elmaci, et al.
Publicado: (2016)

Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?
por: Gao, Rui, et al.
Publicado: (2013)

Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy
por: Yamashita, Fumie, et al.
Publicado: (2013)

Predictive Value of Clinicopathological Factors to Guide Post-Operative Radiotherapy in Completely Resected pN2-Stage III Non-Small Cell Lung Cancer
por: Chien, Ju-Chun, et al.
Publicado: (2023)

Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer
por: Li, Guoping, et al.
Publicado: (2020)

The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival
por: Tantraworasin, Apichat, et al.
Publicado: (2013)

Establishment of cancer/testis antigen profiling based on clinicopathological characteristics in resected pathological stage III non-small cell lung cancer
por: Jin, Shi, et al.
Publicado: (2018)

Prognostic value and clinicopathological significance of epithelial cadherin expression in non-small cell lung cancer
por: Qiu, Zhi-Xin, et al.
Publicado: (2015)

The Association of ERCC1 and ERCC5 Polymorphisms with Lung Cancer Risk in Han Chinese
por: Lan, Xueling, et al.
Publicado: (2022)

Evaluation of Predictive Values of Naples Prognostic Score in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
por: Guo, Dong, et al.
Publicado: (2021)

ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy
por: Xian-jun, Feng, et al.
Publicado: (2014)

Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer
por: Lin, Chang-Sheng, et al.
Publicado: (2017)

Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review
por: Calvo, Virginia, et al.
Publicado: (2021)

Synergistic effects of olaparib combined with ERCC1 on the sensitivity of cisplatin in non-small cell lung cancer
por: Xie, Kejie, et al.
Publicado: (2021)

ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females
por: Yin, Zhihua, et al.
Publicado: (2009)

Prognostic Value Analysis of Mutational and Clinicopathological Factors in Non-Small Cell Lung Cancer
por: Li, Chenguang, et al.
Publicado: (2014)

The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer
por: Feng, Anlin, et al.
Publicado: (2016)

TERT Mutations in Non–Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Implications
por: Yang, Liu, et al.
Publicado: (2023)

Clinicopathological and prognostic significance of Nanog expression in non-small cell lung cancer: a meta-analysis
por: Huang, Guichuan, et al.
Publicado: (2019)

A novel deep learning prognostic system improves survival predictions for stage III non‐small cell lung cancer
por: Yang, Linlin, et al.
Publicado: (2022)

The association between clinical parameters and resectability in stage III non-small cell lung cancer, and a combination of N2 lymph node burden and lung immune prognostic index score as a potential biomarker
por: Kim, Seohyun, et al.
Publicado: (2023)

Prognostic Significance of the Extranodal Extension of Regional Lymph Nodes in Stage III-N2 Non-Small-Cell Lung Cancer after Curative Resection
por: Shih, Beatrice Chia-Hui, et al.
Publicado: (2021)

Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study
por: Vaes, Rianne D. W., et al.
Publicado: (2021)

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
por: Sher, David J.
Publicado: (2017)

Expression levels of ERCC1 and RRM1 mRNA and clinical outcome of advanced non-small cell lung cancer
por: Jian-wei, Bi, et al.
Publicado: (2013)

Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma
por: Zhang, Wen, et al.
Publicado: (2012)

Response to cytotoxic chemotherapy and overall survival in non-small cell lung cancer patients with positive or negative ERCC1 expression
por: Honma, Helen Naemi, et al.
Publicado: (2018)

DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance
por: Wang, Shuai, et al.
Publicado: (2016)

Combined neat model for the prognosis of postoperative stage III‐N2 non‐small cell lung cancer
por: Zhai, Yirui, et al.
Publicado: (2020)

Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2021)

Clinicopathologic features and prognostic implications of NOK/STYK1 protein expression in non-small cell lung cancer
por: Chen, Peng, et al.
Publicado: (2014)

Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer
por: Xie, Liyi, et al.
Publicado: (2018)

Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis
por: Wang, Qingsong, et al.
Publicado: (2020)

Prognostic significance of genetic variants in GLUT1 in stage III non‐small cell lung cancer treated with radiotherapy
por: Kang, Min Kyu, et al.
Publicado: (2021)

Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
por: Vrankar, Martina, et al.
Publicado: (2020)

Epistatic SNP interaction of ERCC6 with ERCC8 and their joint protein expression contribute to gastric cancer/atrophic gastritis risk
por: Jing, Jing-Jing, et al.
Publicado: (2017)

Relevance of ERCC1, RRM1 and BRCA1 in surgically treated non-small cell lung cancer patients
por: Pesta, Martin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_t9uscmmoallhptf7gjsp8v26uh